Reprocessing N95 Masks With STERRAD: Protects Healthcare Workers in the Battle Against COVID-19

The Company ADVANCED STERILIZATION PRODUCTS Thanks FDA for New Guidance to Expedite Solutions in Order to Protect the Public

Advanced Sterilization Products has qualified a new reprocessing protocol that can extend the lifespan of single-use N95 masks (respirators) utilizing STERRAD® Systems already available in most US hospitals and globally.

The evolution of the COVID-19 pandemic has created a mass shortage of N95 masks for healthcare professionals around the world. ASP qualified a protocol for reprocessing select N95 masks so hospitals can triple the lifespan of the mask using the STERRAD® Sterilizers already in healthcare facilities today to reprocess up to 480 masks per STERRAD® Sterilizer machine daily to help healthcare professionals combat the spread of coronavirus.

“We are a company dedicated to keeping people safe, so we are proud to bring forth this new protocol to help extend the functionality of mission-essential N95 masks at this critical time,” said Dominic Ivankovich, President of ASP. “We are committed to provide support to the medical community and continue to work closely with them to implement this new protocol to help keep our HCP heroes safer as they remain at the front-lines in the battle against COVID-19.”

All ASP sterilization systems and disinfectant solutions have been tested against enveloped viruses, the family of viruses that includes coronavirus, and have been demonstrated to be efficacious against those viruses. ASP’s new qualified protocol uses technology already in place in most hospitals to now reprocess certain N95 masks.

“ASP feels responsible to help discover solutions that will aid frontline responders to remain safe in fighting back this pandemic,” said Jeremy Yarwood, Vice President Research & Development, ASP. “The new FDA guidance has allowed us go public with our qualified solution quickly so we can join the effort to overcome shortages of personal protection equipment for healthcare workers worldwide.”

Visit asp.com for complete and up-to-date information on PPE reprocessing, instructions for use of the N95 reprocessing protocol, and 8 Things to consider before reprocessing N95 masks/respirators.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version